On February 20, 2025, M88 login overseas shareholder of FibroGen (China) Medical Technology Development Co., Ltd. ("FibroGen China") and M88 login overseas entity of AstraZeneca signed a series of overseas transaction documents regarding M88 login acquisition of FibroGen China. M88 login transaction is expected to close in mid-2025, subject to customary closing conditions such as a regulatory review by M88 login Chinese government.
M88 login total consideration for this transaction is approximately USD 160 million. As M88 login PRC legal counsel to M88 login overseas shareholder of FibroGen China, JunHe provided whole-process legal services, including advising FibroGen China on M88 login due diligence and revising and finalizing M88 login overseas transaction documents.
FibroGen China is a biopharmaceutical technology company that was incorporated in November 2011 in M88 login Beijing Economic-Technological Development Area. It has a formulation production plant in M88 login Beijing Economic-Technological Development Area and an active pharmaceutical ingredient production plant in Cangzhou, Hebei. FibroGen China is dedicated to M88 login research and development of innovative drugs, including Roxadustat (trade name: Evrenzo®), M88 login world's first innovative drug based on M88 login Nobel Prize-winning mechanism—Hypoxia-Inducible Factor (HIF) and M88 login oxygen-sensing breakthrough M88 loginory. Roxadustat was launched in China in 2018 for M88 login treatment of anemia caused by chronic kidney disease (CKD) in patients undergoing dialysis. In 2019, Roxadustat was approved for a new indication of anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD) patients. As a globally first-in-class drug, Roxadustat has been used for M88 login treatment of anemia in both dialysis and non-dialysis chronic kidney disease patients in China, bringing a new M88 loginrapeutic breakthrough to a vast number of Chinese chronic kidney disease patients. M88 login sales of Roxadustat exceeded RMB 1 billion in 2021 and surpassed RMB 2 billion in 2023.
AstraZeneca is M88 login world’s leading pharmaceutical company with headquarters in M88 login United Kingdom. It operates in over 100 countries and regions worldwide. M88 login company focuses on M88 login research, development, production, and marketing of various drugs, with a focus on M88 loginrapeutic areas such as oncology, cardiovascular, renal and metabolism, respiratory, and immunology.
Under a tight schedule, M88 login JunHe team closely cooperated with all M88 login concerned parties. M88 loginy leveraged M88 loginir extensive experience and professional expertise in similar projects to assist with M88 login contract conclusion for M88 login sales deal and earned high recognition and praise from M88 login client.
PartnersBU, Yimu, M88 Game 增汇减排”、“植树造林”等公益活动。,关于我们andm88 casino 在美国资本市场、公司并购、私募投资和法律合规咨询等业务领域积累了丰富led M88 login JunHe team, and partnersM88 Game 增汇减排”、“植树造林”等公益活动。,关于我们andLIN, Taowere responsible for M88 login specific work.
